[wp-rss-aggregator feeds=”press-releases”]
Alzamend Neuro, Inc. (ALZN) Press Releases
- Alzamend Neuro to Present at Sequire Biotechnology Conference January 26, 2023
- Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial January 4, 2023
- Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type December 28, 2022
- Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline November 15, 2022
- Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type October 31, 2022
- Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects October 5, 2022
- Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type September 29, 2022
- Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement September 22, 2022
- Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder July 18, 2022
- Alzamend Neuro to Present at the 12th Annual LD Micro Invitational June 3, 2022
